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Background: The German COPD cohort study COSYCONET (“COPD and SYstemic consequences-COmor-
bidities NETwork”) investigates the interaction of lung disease, comorbidities and systemic inﬂamma-
tion. Recruitment took place from 2010 to 2013 in 31 study centers. In addition to the baseline visit,
follow-up visits are scheduled at 6, 18, 36 and 54 months after baseline. The study also comprises a
biobank, image bank, and includes health economic data. Here we describe the study design of COSY-
CONET and present baseline data of our COPD cohort.
Methods: Inclusion criteria were broad in order to cover a wide range of patterns of the disease. In each
visit, patients undergo a large panel of assessments including e.g. clinical history, spirometry, body
plethysmography, diffusing capacity, blood samples, 6-min walk-distance, electrocardiogram andannover Medical School, Carl-
linic for Occupational, Social
niversit€at München, Ziems-
. Koch), rudolf.joerres@med.
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Study designechocardiography. Chest CTs are collected if available and CTs and MRIs are performed in a subcohort.
Data are entered into eCRFs and subjected to several stages of quality control.
Results: Overall, 2741 subjects with a clinical diagnosis of COPD were included (59% male; mean age
65 ± 8.6 years (range 40e90)). Of these, 8/35/32/9% presented with GOLD stages IeIV; 16% were
uncategorized, including the former GOLD-0 category. 24% were active smokers, 68% ex-smokers and 8%
never-smokers. Data completeness was 96% for the baseline items.
Conclusion: The German COPD cohort comprises patients with advanced and less advanced COPD. This is
particularly useful for studying the time course of COPD in relation to comorbidities. Baseline data
indicate that COSYCONET offers the opportunity to investigate our research questions in a large-scale,
high-quality dataset.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
With regard to prevalence, mortality and costs, chronic
obstructive pulmonary disease (COPD) is one of the most important
diseases worldwide [1,2]. Although usually progressive, its clinical
course varies considerably between individuals [3,4] and appears to
depend on extrapulmonary comorbidities [5e8], such as cardio-
vascular diseases [9,10], muscle weakness and wasting [11],
depression or anxiety [12], osteoporosis [13] and metabolic disor-
ders [14]. The majority of deceased COPD patients did not die
directly from their pulmonary disease, but from other conditions
[15]. It is not sufﬁciently known, whether these conditions are in-
dependent disorders induced by the same risk factors (e.g. smok-
ing), or whether they are induced and promoted by the lung
disease. Systemic inﬂammation has been suggested to mediate
between the lung disorder and other organ manifestations [16] but
it is not clariﬁed whether this provides a causative link or pre-
dominantly is an epiphenomenon [6,17,18].
The German COPD and systemic consequences-comorbidities
network (COSYCONET) started in 2009 as part of the German
Asthma and COPD Network (ASCONET). COSYCONET speciﬁcally
addresses COPD manifestations beyond the lung, aiming to clarify
whether extrapulmonary organ involvement depends on COPD
severity and conversely, as well as to elucidate the relationship
between systemic inﬂammation and pathologic changes.
This article describes the goals and design of the COSYCONET
cohort study and presents a ﬁrst descriptive analysis of the enrolled
study population. The cohort study is registered on Clinical-
Trials.gov with identiﬁer NCT01245933 and on GermanCTR.de with
identiﬁer DRKS00000284. Further information can be obtained on
the website www.asconet.net.1.1. Network structure
COSYCONET comprises seven subprojects. The cohort study
(subproject 1) is the core of the network, involving the recruitment
and long-term follow-up of a national COPD cohort. Within sub-
project 1, a subcohort is studied regarding sleep disturbances by
polysomnography. Subprojects 2 and 3 focus on the comparison of
COSYCONET patients with reference populations derived from two
population-based cohorts: KORA (“COoperative Health Research in
the Region of Augsburg”) [19,20] and SHIP (“Study of Health In
Pomerania”) [21,22]. These cohorts do not only provide matched
non-COPD controls, particularly for the analysis of comorbidities,
but are also suitable to compare risk factor proﬁles and character-
istics of patients with subclinical (GOLD 0) or mild to moderate
COPD in terms of representativeness of the COSYCONET cohort
when compared to the general population. COSYCONET is supple-
mented by a biobank (subproject 4), an imaging bank (subproject
5), and health economic analyses (subproject 6). In subproject 7, asubcohort of 600 patients from subproject 1 is prospectively
studied with proton magnetic resonance imaging (MRI) for func-
tional and morphological imaging, in comparison to computed
tomography (CT) in inspiration and expiration.
The network is guided by a steering committee and adminis-
tered in a central coordination ofﬁce located at the University of
Marburg. Data management and statistics are performed at
Hannover Medical School. The biobank is located at the University
of Saarland in Homburg and the imaging bank at the University of
Heidelberg. Further support is provided by a scientiﬁc advisory
board and a data safety monitoring board, both with annual
meetings.2. Materials and methods
2.1. Study objectives
The primary aim of COSYCONET is to assess the impact of
extrapulmonary disorders on the risk for progression of COPD and
vice versa. As primary endpoint to deﬁne COPD progression, the
BODE index [23] was chosen as a validated measure to categorize
and predict outcome in COPD. It captures the dimensions Body-
mass index, (airﬂow) Obstruction, Dyspnoea and Exercise capac-
ity. A change in BODE index of one point is considered to be of
clinical relevance [24,25].
Secondary aims are
1. to determine the patterns of extrapulmonary disorders in
COPD of different severity,
2. to assess the joint impact of extrapulmonary disorders,
gender and lifestyle factors onmorbidity, risk for progression
and mortality in COPD,
3. to investigate whether extrapulmonary disorders are prog-
nostic for the development of COPD by comparison with
controls matched from population-based cohorts (KORA and
SHIP),
4. to evaluate the relationship between COPD and the devel-
opment or time course of extrapulmonary disorders and to
determine whether there is a typical sequence,
5. to collect data on morphological alterations of the lung by
available CT scans of the lung,
6. to evaluate the role of age with respect to the function of the
lung and other organs,
7. to assess markers in the blood to evaluate systemic inﬂam-
mation and organ involvement,
8. to investigate whether the pattern of functional and
morphological indices, systemic markers and clinical di-
agnoses allows to deﬁne novel disease phenotypes,
9. to quantify health care utilization and costs induced by
comorbidities vs. the lung disorder,
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assessment of the imaging phenotypes of COPD with CT
serving as the gold standard [26,27].2.2. Study design
COSYCONET is a prospective, observational, multicenter cohort
study [28]. After the baseline visit, subjects are evaluated in follow-
up visits at 6, 18, 36 and 54 months. The study is currently con-
ducted in 31 study centers all over Germany (Fig. 1). Two
population-based German cohorts (KORA, SHIP) are used as refer-
ence populations providing matched controls. Consistency in
questionnaire items and assessments between these cohorts and
COSYCONET has been established as far as feasible. COSYCONET
complies with the Declaration of Helsinki and Good Clinical Prac-
tice Guidelines and has been approved by the ethics committees of
the participating centers and by the concerned data security au-
thority. All participants provided written informed consent.
2.3. Study population
It was planned to include 3.500 patients with a recruitment
strategy primarily based on the cooperation with pneumologists
and general practitioners who were asked to send patients to theFig. 1. Location of all participatingnearby study site. Inclusion criteria were as broad as possible in
order to cover a wide spectrum of presentations of COPD. For
example, it was allowed to recruit subject without a smoking his-
tory and subjects with co-existing asthma.
Patients were enrolled, if the following inclusion criteria were
fulﬁlled:
(i) aged 40 years and older,
(ii) diagnosis of COPD (according to GOLD criteria) or chronic
bronchitis,
(iii) availability for repeated study visits over at least 18 months;
and if none of the following exclusion criteria were fulﬁlled:
(iv) having undergone major lung surgery (e.g. lung volume
reduction, lung transplant),
(v) moderate or severe exacerbation within the last 4 weeks,
(vi) having a lung tumor,
(vii) physical or cognitive impairment resulting in an inability to
walk or to understand the intention of the project.2.4. Measurements
Patients were/are investigated using a broad panel ofstudy centers in COSYCONET.
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and functional state in as much detail as possible within a study
protocol that was still feasible to be performed within one visit.
High priority was given to the assessment of pulmonary function
and cardiovascular comorbidities. Moreover, a huge number of
comorbidities (>50) were systematically recorded by a structured
interview (“Has a medical doctor ever diagnosed the following
comorbidity with you?”).
A standard operating procedure (SOP) was issued with a rec-
ommended order of the scheduled assessments and tests. Table 1
represents this temporal order. Due to logistic reasons echocardi-
ography and CIMT were/are generally performed as the last as-
sessments and bronchodilator administration directly after blood
sampling. Most questionnaires and items for health economics are
sent to the patients at home prior to the visits, except for the SGRQ-
C (to be completed after bioimpedance analysis) and DemTect
(following 6-min walk test).
All procedures are guided by detailed SOPs that are available
through the central ofﬁce and follow common recommendations,
as far as available (see Table 1). Patients are instructed to bring theirTable 1
Scheduled assessments and tests in the COSYCONET cohort study.
Assessment/Test Details
Demography and exposure Basic data, education, profession, previous exposures
Blood and urine samples Panel of samples (systemic inﬂammation, organ-speci
urine; at baseline: 2x EDTA (DNA analysis), BD P100 f
Clinical history Structured interview: comorbidities, familial history, m
Medication Drugs currently used, interview for past medication
Anthropometric data Weight, height, waist/hip ratio, upper thighs circumfe
Blood gas analysis pO2, pCO2, pH, BE; samples from hyperaemic earlobe
Pulmonary function
Bronchodilator administration Prior to measurements 400 mg salb. þ 80 mg ipratropi
Spirometry Standard procedures [33,34]
Body plethysmography Standard procedures [35,36]
Lung transfer factor for CO
(TLCO)
Single breath-maneuver [37]
Bioimpedance analysis (BIA) Resistance & reactance, Fat-free mass index [38]
Cardiology
ECG at rest Supine position, electronic recording and storage
Ankle-brachial index (ABI) Ratio of systolic pressures [39]
Echocardiography Adapted from the German Society for Cardiology
Carotid intima-media
thickness (CIMT)
Optional; standard procedure
Exercise capacity and functioning
Timed up&go Test Functionality test for daily life [40]
6-min walk distance (6-MWD) Standard protocol, Borg scale at beginning and end [4
COPD-related questionnaires
Dyspnoea (mMRC) Modiﬁed MRC dyspnoea scale
Health-speciﬁc QoL (SGRQ-C) COPD-speciﬁc version of St. George Respiratory Quest
COPD Assessment Test (CAT)a) [43]
Health-related questionnaires
Generic QoL (EQ-5D)b) Quality of life measure (5 Items and Visual Analogue S
Anxiety/depression (PHQ-D) Patient Health Questionnaire e Depression [44]
Cognitive impairment
(DemTect)
Sensitive to beginning cognitive impairments [45]
Osteoporosis (FRAX) WHO questionnaire, anthropometric OST-score
Daily physical activity (IPAQ) International Physical Activity Questionnaire [46]
Health economics Medical consultations, hospitalization, rehabilitation,
Supply of chest CT If available (up to 5 years old). Semi-quantitative, stan
Assessments added with the second funding period (performed only at 36 and/or 54 m
Polyneuropathy Rydel-Seiffer tuning fork, monoﬁlament test, symptom
Sputum and pharyngeal
lavage
Spontaneous sputum if possible, standard microbial a
Health economics II Disease management
Functional & morphological
imaging
In 14 study centers/ imaging bank
CT Inspiration/expiration
MRI Dedicated lung protocol
Polysomnography at home In 10 study centers
a COPD Assessment Test is a trade mark of the GlaxoSmithKline group of companies.
b EQ-5D™ is a trade mark of the EuroQol Group. ©EuroQol Group.medication to the study site at each visit; additionally medication is
evaluated via interview.
The study centers were equipped with identical instruments to
assess bioimpedance (Nutribox, Data Input), ECG (ELI 10 electro-
cardiograph, Mortara Instrument GmbH) and ankle-brachial index
(ABI, VascAssist, Isymed). Instruments for lung function testing
were not supplied via COSYCONET, but devices were rather ho-
mogeneous across study sites, a majority of sites using CareFusion
(n ¼ 28) and only 3 sites using Ganshorn or ZAN devices (exclu-
sively or additional to CareFusion). Equipment for echocardiogra-
phy was more heterogeneous: most centers used devices of GE
Healthcare, Philips or Siemens (see appendix).
All scheduled assessments were/are performed at all visits
except for visit 2 (at 6 months) which was shortened by omitting
echocardiography, SGRQ-C, DEMTECT, IPAQ and health economic
questions. Some assessments (see lower part of Table 1) are only
included in the follow-up visits at 36 and/or 54 months. Poly-
somnography and prospective MRI/CT are performed in sub-
populations of the cohort and will be described separately.
COPD severity was determined according to GOLD criteria [29],(smoking, harmful substances/dusts/radiation)
ﬁc markers, telomeres, genome): 2x whole blood for serum, 2x citrate for plasma,
or proteomics, PAXgene for gene expression
edical support, exacerbations in the last 12 months
rence
um bromide
1]
ionnaire [42]
cale)
physiotherapy, absent days from work, medical aids
dardized evaluation/ imaging bank
onths):
score
nalysis
©2009 GlaxoSmithKline group of companies. All rights reserved.
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a ﬁxed value of 70% and being categorized according to the pre-
dicted FEV1 value. Reference values for FEV1 und FVC were derived
using the recent prediction equations from the Global Lung Func-
tion Initiative (GLI) [30], those of ITGV from Koch et al. [31], and
those for TLCO from Cotes et al. [32] with adjustment for hemo-
globin. GOLD severity stages ABCD were determined based on CAT
(and mMRC if CAT not available).
2.5. Quality control and assurance
To reduce errors during data capture and ensure standardized
data collection across study sites, the following measures were
taken:
Extensive plausibility checks and explanatory comments were
implemented to the eCRFs. A detailed user manual for data entry
and monitoring and SOPs for each medical assessment and ques-
tionnaire were provided, combined with regular (at least annual)
training of the clinical investigators and data entry users. Calibra-
tions were/are scheduled on a daily basis for spirometric measures
and at least every week for body plethysmography and diffusing
capacity.
Incoming data was intensively monitored by permanent data
quality checks [47] followed by online queries. Periodic monitoring
reports were/are issued and sent to the study centers and the co-
ordination ofﬁce via email: (1) Site-speciﬁc reports are prepared on
a monthly basis providing support for the organization of study
visits (due and overdue patients) as well as for timely eCRF entry
and signature. Site-speciﬁc problems and open queries are issued in
tables. (2) Additionally, site-speciﬁc query listings resulting from
advanced quality analyses of the data set are sent to the study sites.
(3) Quarterly overall quality reports are issued with the number of
patients per visit, number and reasons for drop-out, information on
completeness and results of benchmark quality analyses where
mean values and frequencies of relevant variables are compared
across centers. Special emphasis is placed on extensive quality
control of lung function and ECG, including for instance visual in-
spection of spirometric curves performed centrally by a lung
function expert, if necessary.
2.6. Statistical methods
Sample size estimation was performed prior to the study and
targeted at 90% power for detecting associations between a speciﬁc
risk factor (especially comorbidities) and a one-point increase in
BODE scores with an Odds Ratio greater than 1.5. Calculations were
done under various assumptions (homogeneity or heterogeneity
across GOLD I/II and III/IV strata, different prevalence rates for
comorbidities) and resulted for most scenarios in an adequate po-
wer (around 80%) for detecting Odds Ratios greater 1.25 at visit 3
with n ¼ 3000 patients.
The primary analysis strategy to be applied after the third visit at
18 months is the following: Univariate Odds Ratios will be used to
assess the impact of a certain systemic manifestation or risk factor
on the risk for progression in an individual patient (deﬁned as an
increase of 1 point in the BODE index). Variables identiﬁed as
prognostic will be included in a logistic regression model that also
includes established risk factors (such as age) for the joint assess-
ment of their impact on disease progression. Backward selection
will be used to identify a parsimonious model, and sensitivity an-
alyses to further explore the impact of competing variables for the
description of a certain systemicmanifestation. Besides this, further
modelling strategies will be applied (ﬁxed effects modelling with a
priori set basic variables). The same approach will be used for
mortality and hospitalization data. Cox regression will be used toinvestigate the joint impact of potential risk factors on time-to-
event data.
Results presented in this article provide the cross-sectional,
descriptive analysis of the COSYCONET data obtained at baseline.
Means and standard deviations are given for numeric variables. For
categorical variables, absolute and relative frequencies are pre-
sented. Analysis was performed in SAS 9.3. The article does not
include results of the population-based cohorts KORA and SHIP.
Basic results of these cohorts have been provided in previous
publications (e.g. Refs. [48e51]). A direct, detailed comparisonwith
COSYCONET data is to be presented in separate papers.
3. Results
3.1. Recruitment
A total of 2741 patients were recruited from September 2010 to
December 2013 in 31 study centers throughout Germany. After
study initiation, a pilot phase of three months duration was con-
ducted in selected study sites, and the study was continued up from
January 2011.
Since the original recruitment strategy was not as successful as
expected, the mode of recruitment was extended to outpatient
clinics, patient groups and organizations and to advertising in local
media (Fig. 2). Considering the study period from July 2011 to
recruitment termination, the mean recruitment rate was 85 pa-
tients per month. Most of the centers contributed very well to
patient recruitment: 25 centers included more than 50 patients,
many of them (12 centers) even more than 100 patients, and only
one study site recruited less than 10 patients. The most active study
center enrolled 259 patients.
3.2. GOLD stages
Classiﬁcation into severity stages according to GOLD [29]
resulted in 206/962/874/249 patients of stages IeIV, correspond-
ing to 8%/35%/32%/9% of the total study population (Fig. 3).
Expressed in GOLD stages ABCD, which are additionally based on
symptoms and risk for exacerbations [29], the distribution is 184
(7%)/672 (25%)/104 (4%)/1322 (48%) for A/B/C/D, respectively. Pa-
tients not categorized into GOLD IeIV were not classiﬁed into GOLD
AeD.
During the early recruitment period, data quality checks
revealed a proportion of patients (10e15%) exhibiting a Tiffeneau-
index (FEV1/FVC) above 70% at the baseline visit and thus not ful-
ﬁlling the inclusion criteria of at least GOLD stage I. Intense dis-
cussions of this issue led to the decision to further analyze and
follow these patients and to relax the respective inclusion criterion.
A major argument was, that the high-dose bronchodilator admin-
istration (used to standardize the patients' condition prior to
functional assessments) could have induced an improvement in
spirometric lung function that raised these patients above the
thresholds used to deﬁne COPD stage I. Hence we also recruited
patients of the former GOLD category 0 [52,53].
GOLD 0 was deﬁned as having a Tiffeneau-index > 70% and
either (i) having a doctor diagnosis of chronic bronchitis and/or (ii)
indicating a severity of cough of at least 3 in the respective CAT item
and/or (iii) indicating a severity of phlegm of at least 3 in the
respective CAT item. A total of 354 patients (13%) were classiﬁed as
GOLD 0 according to these criteria. Some patients with a Tiffeneau
>70% did not fulﬁl the conditions for GOLD 0 upon re-examination
and formed the group of “GOLD unclassiﬁed” (n ¼ 76, 3%). For
additional 20 patients, GOLD stages were not assessable due to
missing variables for classiﬁcation. For a comprehensive presenta-
tion of results, patients not fulﬁlling GOLD 0eIV and patients with
Fig. 2. Sources of recruitment.
Fig. 3. Flow-chart of patient inclusion (*Unclassiﬁed means that patients had the diagnosis of COPD but at the time of study inclusion normal lung function and no chronic
symptoms of bronchitis.).
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throughout the results section.3.3. Baseline characteristics
The descriptive results for selected baseline characteristics are
presented in Table 2. Patients were aged 40e90 years, with a mean
age of 65 years. There were more males (59.1%) than females
(40.9%). Patients had a mean duration of diagnosed COPD of 7.7
years, with an interquartile range from 3 to 10 years. 24% of in-
dividuals enrolled were currently smoking, 68% ex-smokers and 8%
never-smokers. Smokers and ex-smokers reported on average
45e50 pack-years. The percentages of (ex-) smokers as well as the
amount of pack-years were lower in the GOLD-0 group and un-
classiﬁed patients. In general, BMI was high with a mean value of27 kg/m2. BMI was reduced in GOLD-IV patients and showed higher
values in GOLD-0 and unclassiﬁed patients.
The spirometric data demonstrated the impairment to be ex-
pected owing to the COPD classiﬁcation. A strong difference be-
tween GOLD stages could be observed for exercise capacity, with 6-
min walk distance decreasing from nearly 500 m in GOLD-I to
330 m in GOLD-IV. Likewise, the time for the Timed up&go Test
(overall mean 7 s) increased across GOLD stages. GOLD-0 and un-
classiﬁed patients showed an exercise capacity comparable to
GOLD-II/III patients. The primary endpoint of this study, the BODE
index (having a possible range from 0 to 10) was on average 2.2,
with strong differences between GOLD stages.
Obviously, the number of comorbidities and a high average of
medications per patient (6.7) reﬂect the advanced age of the study
population (Table 3). Comorbidities were fairly homogeneously
Table 2
Baseline characteristics of the COSYCONET cohort.
Missings
(In total)
Total (n ¼ 2741) GOLD-I
(n ¼ 206)
GOLD-II
(n ¼ 962)
GOLD-III
(n ¼ 874)
GOLD-IV
(n ¼ 249)
GOLD-0
(n ¼ 354)
Unclassiﬁed
(n ¼ 96)
Demography and exposure
Age (years) 0 65.1 ± 8.6 66.2 ± 8.7 65.7 ± 8.5 65.0 ± 8.2 62.1 ± 7.9 64.6 ± 9.7 66.7 ± 9.2
Male sex 0 1619 (59%) 124 (60%) 579 (60%) 533 (61%) 160 (64%) 176 (50%) 47 (49%)
Educationa 19
High 480 (18%) 54 (26%) 185 (19%) 130 (15%) 32 (13%) 63 (18%) 21 (22%)
Intermediate 740 (27%) 52 (25%) 275 (29%) 220 (25%) 73 (29%) 97 (28%) 26 (27%)
Low 1482 (55%) 98 (48%) 495 (52%) 522 (60%) 143 (58%) 188 (54%) 48 (51%)
Full- and part-time employees 13 590 (22%) 50 (24%) 228 (24%) 157 (18%) 35 (14%) 93 (26%) 27 (28%)
Smoking 4
Current smoker 666 (24%) 62 (30%) 277 (29%) 190 (22%) 36 (15%) 86 (24%) 15 (16%)
Ex-smoker 1852 (68%) 129 (63%) 610 (64%) 634 (73%) 199 (80%) 213 (60%) 67 (70%)
Never smoker 219 (8%) 15 (7%) 73 (8%) 49 (6%) 13 (5%) 55 (16%) 14 (15%)
Pack-yearsb 234b 47.9 ± 35.7 45.1 ± 31.2 51.0 ± 37.7 48.4 ± 34.9 48.1 ± 33.4 40.4 ± 36.2 43.2 ± 32.9
Clinical history
Years of COPD 25 7.7 ± 7.0 7.2 ± 7.1 7.5 ± 7.0 8.4 ± 7.1 8.6 ± 5.7 6.7 ± 6.9 6.2 ± 7.7
Exacerbations in last 12 months 1 1.3 ± 2.6 0.6 ± 1.2 1.1 ± 2.5 1.6 ± 3.0 1.9 ± 2.8 1.2 ± 2.7 0.5 ± 1.0
Anthropometric data
Weight 2 79.1 ± 18.1 79.0 ± 15.5 80.7 ± 17.4 77.2 ± 18.4 71.3 ± 17.3 83.6 ± 18.4 84.2 ± 19.5
Height 0 170.7 ± 9.1 172.0 ± 8.4 171.2 ± 9.1 170.5 ± 9.3 170.4 ± 8.6 169.5 ± 9.3 170.3 ± 9.6
BMI (kg/m2) 2 27.0 ± 5.4 26.6 ± 4.6 27.4 ± 5.1 26.4 ± 5.4 24.4 ± 5.0 29.0 ± 5.8 28.8 ± 5.2
Pulmonary function
FEV1 (%predicted) 16 56.9 ± 21.2 88.6 ± 8.1 62.7 ± 8.3 40.7 ± 5.6 24.8 ± 3.9 80.6 ± 18.8 78.1 ± 19.6
FVC (%predicted) 20 78.6 ± 19.0 106.8 ± 10.8 86.3 ± 12.9 69.8 ± 13.4 52.4 ± 13.0 81.0 ± 18.3 79.8 ± 17.1
Exercise capacity and functioning
6-min walk distance (metres) 77 419 ± 109 487 ± 87 443 ± 94 391 ± 103 329 ± 110 441 ± 113 421 ± 115
Timed up&go test (seconds) 72 7.0 ± 2.4 6.2 ± 2.1 6.8 ± 2.3 7.1 ± 2.2 7.7 ± 2.8 7.2 ± 2.6 7.4 ± 2.5
Primary endpoint of COPD impairment
BODE index 117 2.2 ± 2.0 0.4 ± 0.7 1.3 ± 1.2 3.6 ± 1.5 5.3 ± 1.6 1.0 ± 1.4 0.9 ± 1.4
a Education is categorized according to years of school education: Low: 9 years, Intermediate: ¼ 10 years, High:  11 years or university degree.
b Pack-years were computed excluding never smokers.
Table 3
Prevalences of selected self-reported comorbidities and classes of medication at baseline.
Comorbidities Total
(n ¼ 2741)
Medication Total
(n ¼ 2741)
Asthma 509 (18.6%) Respiratory-related medication
Chronic bronchitis 1710 (62.4%) Rapid-acting Beta-2-agonists 1076 (39.3%)
Sleep apnea 308 (11.2%) Long-acting Beta-2-agonists 965 (35.2%)
Hypertension 1545 (56.4%) Rapid-acting anticholinergics 125 (4.6%)
Coronary artery disease 436 (15.9%) Long-acting anticholinergics 1893 (69.1%)
Cardiac infarction 225 (8.2%) Theophylline 491 (17.9%)
Cardiac dysrhythmia 247 (16.9%) Inhalative steroids 479 (17.5%)
Heart failure 148 (10.1%) Oral steroids 325 (11.9%)
Stroke 120 (4.4%) Anticholinergic þ Beta-2-agonist 545 (19.9%)
Venous thrombosis 197 (7.2%) Bronchodilator þ inhalative C.steroids 1267 (46.2%)
Gastritis 692 (25.3%)
GE reﬂux disease 414 (28.3%) Cardiovascular medication 1806 (65.9%)
Peptic ulcer 325 (11.9%)
Diabetes with insulin 143 (5.2%) Sum of any taken medication 17,897
Diabetes without insulin 247 (9.0%) Medication per patient (mean ± sd) 6.7 ± 3.7
Elevated cholesterol level 1072 (39.1%)
Gout 465 (17.0%)
Alpha-1-antitrypsin deﬁciency 168 (6.1%)
Tumor general 315 (11.5%)
Arthrosis 1099 (40.1%)
Arthritis 248 (9.1%)
Osteoporosis 409 (14.9%)
Psychiatric disorders 583 (21.3%)
Cognitive impairment 153 (5.6%)
Peripheral neuropathy 178 (6.5%)
Allergy overall 919 (33.5%)
A. Karch et al. / Respiratory Medicine 114 (2016) 27e37 33distributed over COPD stages; this and their relationship to function
will be analyzed in detail in forthcoming papers.
3.4. Data quality
The overall data quality in terms of completeness andplausibility was/is very high. Overall completeness across all CRFs
of the baseline visit was 96%. Most of the missing values were
attributable to echocardiography, either because of limitations in
single study centers (e.g. in echocardiographic devices) or because
of poor sonographic conditions in patients. Leaving echocardiog-
raphy CRFs out of overall calculation, completeness increases to
A. Karch et al. / Respiratory Medicine 114 (2016) 27e373498.5%. A large number of plausibility analyses were established
during the recruitment phase and were intensiﬁed in the data
cleaning phase. All queries related to the baseline visit were
answered, and procedures were set to handle further implausible
patterns becoming apparent in the advanced statistical analysis.4. Discussion
The COSYCONET cohort is a large national multicenter COPD
cohort studied by a comprehensive set of assessments and follow-
up visits. It focusses on the time course and relationship between
lung disease and comorbidities. The cohort comprises the full
spectrum of COPD severities, starting with the former disease
category GOLD 0. The assessments include functional tests and
questionnaires and have been designed to cover important aspects
of COPD and establish comparability with known data. In the ma-
jority of patients echocardiographic data are available allowing an
in-depth evaluation of cardiac comorbidities in a large, well char-
acterized COPD cohort.
COSYCONET was originally powered with 90% to detect risk
factors (especially comorbidities) that lead to an increase in the
Odds Ratio greater than 1.5 for relevant BODE worsening. The ﬁnal
sample size (n¼ 2741 at visit 1, n ¼ 2000e2200 expected at visit 3)
was lower than the initially planned sample size (n ¼ 3000 at visit
3) but still provides a power of 70e80% for detecting Odds Ratios
greater than 1.5.
Most of the patients were male as expected from the course of
smoking habits over time and the duration of smoking needed to
develop COPD. Despite this, women already accounted for more
than one third of patients. For data analysis this is encouraging
because it suggests that we have the statistical power to investigate
sex differences in the risk proﬁle of the disease.
The patients' baseline characteristics regarding functional and
questionnaire results were those typically seen in COPD cohorts,Table 4
Basic characteristics of longitudinal COPD cohorts.
Cohort Recruitment N N COPDa Age
COPDa
Male
COPDa
COSYCONET 2009e2012
Germany
2741 2291 65.1 59%
Bergen cohort
[54e56]
2006e2007
Norway
758 433 63.6 60%
INITIATIVES BPCOb
[57]
2002-ongoing
France
1194 1194 64.0 75%
CanCOLD
[58,59]
2005e2009
Canada
4893 557 61.9 43%
COPDGene
[60]
2008e2011
USA
10,300 4484 63.3 56%
ECLIPSE
[4]
2005e2007
multinational
2746 2163 61.6 65%
Hokkaido cohort
[61,62]
2003e2005
Japan
300 279 70.0 94%
London cohortb
[63,64]
1995e2009
UK
386 386 68.4 58%
Swiss cohort
[65]
2007e2010
Switzerland
454 354 68.1 66%
Data that were not directly given in the cited publication(s) were computed from available
weighted mean of age from different subgroups).
a COPD as deﬁned by GOLD [29] with FEV1/FVC  0.70.
b Recent data was obtained from personal communication in February 2016.suggesting that the cohort is not selected to a degree to be funda-
mentally different from other cohorts. This is not a trivial issue
since the very broad inclusion criteria could have resulted in the
inclusion of many “untypical” patients who would have been
excluded in other studies. A direct comparison of the COSYCONET
cohort with other COPD cohorts (Table 4) shows that the baseline
characteristics are completely within the range observed in the
other cohorts. In this respect, COSYCONET is comparable and does
not suffer from speciﬁc biases resulting e.g. from the recruitment
procedures. Some of the other cohorts include control groups. In
COSYCONET, the external population-based cohorts KORA and SHIP
have this purpose. Moreover, patients of the GOLD category 0, who
have been recruited exactly the same way as those of categories
1e4, allow for the comparison with the large number of patients
with normal lung function in KORA and SHIP regarding the pattern
and distribution of comorbidities which might have favored in-
clusion in COSYCONET.
This comparability to other COPD cohorts also offers possibil-
ities for pooling COSYCONET data with those from other large co-
horts for the purpose of clustering of phenotypes or checking the
robustness of relationships between disease characteristics. The
patterns of comorbidities as well as their relationship to functional
measures, questionnaire data and medication will be analyzed in
detail in forthcoming papers.
Only a minority of COSYCONET patients had stage IV disease.
The most likely explanation is that many of these patients are
handicapped to a degree that they were not capable of performing
the assessments. It is clear that the study protocol is demanding,
although (given enough time) in the experience of most in-
vestigators it was manageable even for patients of GOLD stage IV.
Despite this, at the end of the recruitment period these patients
were underrepresented and it has to be assumed that participating
GOLD stage IV patients are “healthier” than common stage IV pa-
tients. With regard to the aim of the study, we do not consider theGOLD stages Other participants, N
I II III IV
206
(9%)
962
(42%)
874
(38%)
249
(11%)
 GOLD “0”
 Unclassiﬁed
354
96
0
(0%)
204
(47%)
180
(42%)
49
(11%)
 Healthy 325
110
(9%)
538
(45%)
349
(29%)
197
(17%)
e e
242
(43%)
315
(57%)
 Smoking
 Non-Smoking
2202
2134
794
(18%)
1922
(43%)
1162
(26%)
606
(13%)
 Unclassiﬁed
 Smoking GOLD “0”
 Non-Smoking
1320
4388
108
2
(0.1%)
954
(44%)
911
(42%)
296
(14%)
 Unclassiﬁed
 Smoking
 Non-Smoking
1
337
245
72
(26%)
126
(45%)
68
(24%)
13
(5%)
 GOLD “0” 21
0(0%) 158(41%) 148(39%) 78(20%) e e
43
(12%)
164
(46%)
119
(34%)
28
(8%)
 GOLD “0” 100
data in the respective publication (e.g. we calculated overall age in some cases as the
Device from… Study centers using the device % of study centers
General Electric LOGIQ 3 10%
General Electric VIVID 18 58%
Hitachi 1 3%
Philips 18 58%
Siemens 5 16%
Toshiba 2 6%
A. Karch et al. / Respiratory Medicine 114 (2016) 27e37 35underrepresentation as a major disadvantage. These patients have
reached the ﬁnal stage of the disease which suggests that the
chance to gain additional insights regarding the development of
comorbidities is limited. Probably clinical questions regarding stage
IV patients are better answered in speciﬁc studies. Nonetheless,
patients of this stage are important in the cohort in order to com-
plete the spectrum of the disease. In addition, some patients of
lower stages are expected to progress into stage IV; therefore, this
group will not necessarily become much smaller over time despite
its excess mortality.
In contrast, there could be reason to be concerned in view of the
small proportion of patients of stage I, as these patients seem to be
the primary candidates for a long-term follow-up aiming to assess
the course of COPD and comorbidities. First, it is known that many
early stage patients cope with their functional limitations without
consulting a physician. A second factor appears to be that the high-
dose bronchodilator administration that we used to standardize the
patients' condition prior to functional assessments, may have
raised these patients above the thresholds used to deﬁne COPD
stage I. Prior to this medication patients might have been of stage I,
despite having taken their regular medication, but afterwards no
more. Since most of the patients also reported respiratory symp-
toms such as cough and phlegm, they were classiﬁed into the
former category of COPD stage 0, which was deﬁned by chronic
symptoms without signiﬁcant airﬂow limitation, or a previous
doctor diagnosis of COPD.
These circumstances have enabled us to recruit about 350 pa-
tients of stage GOLD 0. Discussions about the usefulness of deﬁning
a GOLD 0 “at risk” stage were held in the past [66e68] and stage
0 has been excluded from GOLD strategy reports in 2006 [69].
Conversely, studies suggested that subjects of the stage 0 are at risk
for developing COPD and comorbidities and for experiencing
increased mortality [70]. We thus included these subjects in a
controlled manner, requiring chronic symptoms of cough and
phlegm as required by the former GOLD criteria. In concordance
with the former GOLD deﬁnition we did not demand a smoking
history.
5. Conclusions
To our knowledge this is the ﬁrst large COPD cohort that has a
focus on lung and comorbidities with a long-term follow-up
concept. Recruitment resulted in 2741 patients of all COPD
severity stages, for whom data of a large panel of assessments was
collected in very high data quality. The follow-up is ongoing. We
expect ﬁrst results on the relationship between disease charac-
teristics after the 18-month follow-up visit and additional insight
from the further visits extending up to (at least) 54 months after
inclusion.
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